In estrogen receptor positive (ER+) breast cancer therapy, estrogen receptors (ERs) are the
major targeting molecules. ER-targeted therapy has provided clinical benefits for …

Endocrine therapy has led to a significant improvement in outcomes for women with
estrogen receptor–positive (ER+) breast cancer. Current questions in the adjuvant setting …

Estrogen receptor (ER) α is expressed in the vast majority of breast cancers and is one of the
most successfully prosecuted drug targets in oncology, with multiple classes of endocrine …

Estrogen receptor (ER) signaling represents the main driver of tumor growth and survival in
hormone receptor positive (HR+) breast cancer (BC). Thus, endocrine therapy (ET) alone or …

Estrogen receptor (ER) has a crucial role in normal breast development and is expressed in
the most common breast cancer subtypes. Importantly, its expression is very highly …

Nearly 80% of all breast cancers are estrogen receptor positive (ER+) and require the
activity of this transcription factor for tumor growth and survival. Thus, endocrine therapies …

Abstract Purpose of Review Estrogen receptor-positive (ER+) breast cancer represents the
majority of breast cancer diagnoses and is the leading cause of cancer death in women …

There are large-scale molecular differences between estrogen receptor (ER)-positive and
ER-negative breast cancers. Endocrine therapy has become the most important treatment …

Simple Summary The estrogen receptor (ER) plays a critical role in the initiation and
progression of breast cancer. Utilizing specialized therapies aimed at the ER has been …

In up to 75% of breast cancers, estrogen receptor (ER) signaling is a key promoter of tumor
proliferation, and inhibition of this pathway has clear therapeutic efficacy. The principal …